baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

CRISPR THERAPEUTICS AG NAM.-AKTI/ CH0334081137 /

2024-04-19 10:01:21 PM	Chg. +0.50	Volume	Bid-	Ask-	High	Low
52.00EUR	+0.97%	- Turnover: -	-Bid Size: -	-Ask Size: -	52.00	51.50

GlobeNewswire 04-03 CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

GlobeNewswire 04-01 CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Me...

GlobeNewswire 03-13 CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire 02-21 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial...

GlobeNewswire 02-15 CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

GlobeNewswire 02-13 CRISPR Therapeutics Announces $280 Million Registered Direct Offering

GlobeNewswire 02-13 European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemc...

GlobeNewswire 01-16 CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamgl...

GlobeNewswire 01-03 CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

TeleTrader 2023-12-08 US FDA approves first gene editing treatment

GlobeNewswire 2023-12-04 CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Dise...

GlobeNewswire 2023-11-06 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-11-06 CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Se...

GlobeNewswire 2023-10-31 CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotem...

GlobeNewswire 2023-10-31 CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Applica...

GlobeNewswire 2023-10-16 CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire 2023-09-27 CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

GlobeNewswire 2023-09-07 CRISPR Therapeutics Announces Leadership Transition

GlobeNewswire 2023-08-30 CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference

GlobeNewswire 2022-03-08 CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 20...

GlobeNewswire 2022-02-28 CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 2022-02-15 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial...

GlobeNewswire 2022-02-09 CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire 2022-02-02 CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Nove...

GlobeNewswire 2021-11-23 CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR THERAPEUTICS AG NAM.-AKTI/ CH0334081137 /

If you wish to receive reply to your feedback, please provide your email address.